Cesne, A. L., Judson, I., Maki, R., Grosso, F., Schuetze, S., Mehren, M. V., Chawla, S. P., Demetri, G. D., Nieto, A., Tanovic, A., Blay, J. Y. (October 2013) Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer, 109 (7). pp. 1717-24. ISSN 1532-1827 (Electronic)0007-0920 (Linking)
Abstract
BACKGROUND: This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS). METHODS: Data from 350 adults with STS treated in five phase II trials with trabectedin were divided in the younger (<60 years; n=267) and the older cohort (>/=60 years; n=83). RESULTS: The response rate did not differ with age (younger: 10.1% vs elderly 9.6%). No significant differences were found in median progression-free survival (PFS) in younger (2.5 months) and older (3.7 months) cohort with a comparable PFS rates at 3 (45.1% vs 55.1%) and 6 months (29.5% vs 36.4%). Similar median overall survival was observed in both cohorts (13.0 vs 14.0 months). Reversible neutropenia and aspartate aminotransferase/alanine aminotransferase elevation were the most common abnormalities. A higher incidence of grade 3/4 neutropenia (43.6% vs 60.2%) and fatigue (6.3% vs 14.4%) was observed in older patients. In 24 patients aged >/=70 years, no significant differences in efficacy or safety outcomes were found. CONCLUSION: This analysis demonstrated that trabectedin is a feasible treatment in young and elderly patients with STS, with meaningful clinical benefits and an acceptable safety profile, essential in palliative treatment of elderly patients.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Age Factors Aged Aged, 80 and over Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use Dioxoles/adverse effects/*therapeutic use Disease-Free Survival Female Humans Male Middle Aged Retrospective Studies Sarcoma/*drug therapy/*mortality Tetrahydroisoquinolines/adverse effects/*therapeutic use Treatment Outcome Young Adult |
| Subjects: | diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | 1 October 2013 |
| Date Deposited: | 20 Oct 2016 15:57 |
| Last Modified: | 20 Oct 2016 15:57 |
| PMCID: | PMC3790176 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33746 |
Actions (login required)
 |
Administrator's edit/view item |